Scripps VIVO scripps research logo

  • Index
  • Log in
  • Home
  • People
  • Organizations
  • Research
  • Events
Search form
As of April 1st VIVO Scientific Profiles will no longer updated for faculty, and the link to VIVO will be removed from the library website. Faculty profile pages will continue to be updated via Interfolio. VIVO will continue being used behind the scenes to update graduate student profiles. Please contact helplib@scripps.edu if you have questions.
How to download citations from VIVO | Alternative profile options

Anti-LRP/LR specific antibody IgG1-iS18 and knock-down of LRP/LR by shRNAs rescue cells from A beta(42) induced cytotoxicity

Academic Article
uri icon
  • Overview
  • Identity
  • Additional Document Info
  • View All
scroll to property group menus

Overview

authors

  • Da Costa Dias, B.
  • Jovanovic, K.
  • Gonsalves, D.
  • Moodley, K.
  • Reusch, U.
  • Knackmuss, S.
  • Penny, C.
  • Weinberg, Marc
  • Little, M.
  • Weiss, S. F. T.

publication date

  • 2013

journal

  • Scientific Reports  Journal

abstract

  • Alzheimer's disease (AD) is characterized by neurofibrillary tangles, senile plaques and neuronal loss. Amyloid beta (Aβ) is proposed to elicit neuronal loss through cell surface receptors. As Aβ shares common binding partners with the 37 kDa/67 kDa laminin receptor (LRP/LR), we investigated whether these proteins interact and the pathological significance of this association. An LRP/LR-Αβ42 interaction was assessed by immunofluorescence microscopy and pull down assays. The cell biological effects were investigated by 3-(4,5-Dimethylthaizol-2-yl)-2,5-diphenyltetrazolium bromide and Bromodeoxyuridine assays. LRP/LR and Αβ42 co-localised on the cell surface and formed immobilized complexes suggesting an interaction. Antibody blockade by IgG1-iS18 and shRNA mediated down regulation of LRP/LR significantly enhanced cell viability and proliferation in cells co-treated with Αβ42 when compared to cells incubated with Αβ42 only. Results suggest that LRP/LR is implicated in Αβ42 mediated cytotoxicity and that anti-LRP/LR specific antibodies and shRNAs may serve as potential therapeutic tools for AD.

subject areas

  • Amyloid beta-Peptides
  • Antibodies, Monoclonal
  • Cell Line
  • Cell Membrane
  • Down-Regulation
  • Gene Expression Regulation
  • Gene Knockdown Techniques
  • Humans
  • Protein Binding
  • Protein Transport
  • RNA, Small Interfering
  • Receptors, Laminin
scroll to property group menus

Identity

PubMed Central ID

  • PMC3776967

International Standard Serial Number (ISSN)

  • 2045-2322

Digital Object Identifier (DOI)

  • 10.1038/srep02702

PubMed ID

  • 24048171
scroll to property group menus

Additional Document Info

start page

  • 2702

volume

  • 3

©2022 The Scripps Research Institute | Terms of Use | Powered by VIVO

  • About
  • Contact Us
  • Support